{"groups":[{"description":"apixaban 2.5 mg orally twice daily for primary prevention of VTE for a duration of 6 months\n\nApixaban: apixaban 2.5 mg orally twice daily for primary prevention of VTE for a duration of 6 months","id":"FG000","title":"Apixaban"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"50"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"50"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}